MediaMedic

Omission of surgery in early breast cancer: Are we ready for a paradigm shift?

By Mourabit Halima 2025.05.19

In a recent ESSO Research Academy survey led by Carmela Caballero and co-authored by Prof. Isabel T. Rubio, Prof. Evandro de Azambuja, and Prof. Stuart A. McIntosh, both clinicians and…

Advancing precision oncology with metabolomics and machine learning

By Yin, Jiale 2025.05.19

A new study led by Dr. Rafael Nambo Venegas and colleagues, published in Metabolomics (Feb 2025), presents a high-accuracy predictive model for forecasting response to neoadjuvant therapy in breast cancer…

Risk-based breast cancer screening: A shift toward personalized prevention

By Mourabit Halima 2025.05.19

In a recent study published in December 2024, Professor Isabel Rubio and her colleagues critically examined the limitations of current age-based breast cancer screening programs, which remain standard in most…

Temocillin in the Spotlight: Dr. Francesco Cogliati Dezza on Tackling Antimicrobial Resistance

By Mourabit Halima 2025.05.14

At ESCMID Global 2025, Infectious Disease Frontier interviewed Dr. Francesco Cogliati Dezza to explore the renewed clinical relevance of temocillin. With resistance to broad-spectrum antibiotics on the rise, temocillin is…

Professor Li Zhang’s Team Publishes Again in Nature Medicine

By Mourabit Halima 2025.05.12

On April 10, 2025, a research team led by Professor Li Zhang and Professor Wenfeng Fang from Sun Yat-sen University Cancer Center published a significant study in the world-renowned journal…

Mok Talk | Lung Cancer Leadership, Innovation, and the Power of Collaboration

By Peng Longmei 2025.05.09

In this special episode of Mok Talk, Professor Tony Mok (The Chinese University of Hong Kong) sits down with three rising oncology experts Professor Yang Xia (Zhejiang University), Professor Wenhua…

Temocillin in the Spotlight: Dr. Francesco Cogliati Dezza on Tackling Antimicrobial Resistance

By Mourabit Halima 2025.05.09

At ESCMID Global 2025, Infectious Disease Frontier sat down with Dr. Francesco Cogliati Dezza to discuss the renewed clinical relevance of temocillin. As resistance to broad-spectrum antibiotics continues to rise,…

Advancing the Diagnosis and Prevention of Congenital CMV: Insights from Dr. Marianne Leruez-Ville

By Mourabit Halima 2025.05.08

At ESCMID Global 2025, one of the world’s leading forums for infectious disease and clinical microbiology, congenital cytomegalovirus (CMV) took center stage as experts explored new avenues in screening, prevention,…

Temocillin and the Search for Carbapenem Alternatives: A Conversation with Dr. Francesco Cogliati Dezza at ESCMID Global 2025

By Peng Longmei 2025.05.08

At ESCMID Global 2025, antimicrobial resistance stood out as one of the most pressing topics. As carbapenem resistance rises to alarming levels worldwide, the medical community is urgently seeking viable…

Prof. Lin Visits MGH | Talk with Prof. Lori Wirth on Targeted Therapy for Advanced Thyroid Cancer

By Mourabit Halima 2025.05.08

Join us for an exclusive conversation between Prof. Yansong Lin of Peking Union Medical College Hospital and Prof. Lori Wirth at Massachusetts General Hospital. In this special academic exchange, the…

Summit Dialogue | Professors Zhang Guojun & Michael Gnant: New Frontiers in Neoadjuvant Therapy for HER2-Positive Breast Cancer

SABCS China Voice | Professor Wang Biyun: Beware of ER Loss — Study Reveals Poor Prognosis in Patients Converting from ER-Positive to ER-Negative

SABCS China Voice | Prof. Wang Yongsheng: Ki-67–Guided Precision Strategies and Multi-Omics Insights Reshape Breast Cancer Neoadjuvant Therapy

SABCS China Voice | Prof. Wang Yongsheng: Ki-67–Guided Precision Strategies and Multi-Omics Insights Redefine Neoadjuvant Breast Cancer Treatment

SABCS China Voice | Professors Yan Min & Lü Huimin: U-BOMB-HER Study Advances Treatment of HER2-Positive Brain Metastases

SABCS China Voice | Professor Yan Min’s Team: Post-PERMEATE Study Clarifies Radiotherapy Timing in HER2-Positive Brain Metastases

ASH Global Perspectives | Prof. Hanny Al-Samkari: Efficacy, Safety, and Dose Optimization of Ianalumab + Eltrombopag in Second-Line ITP

ASH Global Perspectives | Professor Jeff Sharman: How Can We Reshape Treatment Strategies for Elderly Patients With DLBCL?

ASH Global Perspectives | Prof. Fabio Efficace’s Team: Advances in Patient-Reported Outcomes in Hematology

New Breakthrough in Targeting BAFF Pathway: Ianalumab Significantly Prolongs Time to Treatment Failure in ITP Patients — A Detailed Look at VAYHIT 2

Summit Dialogue | Professors Zhang Guojun & Michael Gnant: New Frontiers in Neoadjuvant Therapy for HER2-Positive Breast Cancer

SABCS China Voice | Professor Wang Biyun: Beware of ER Loss — Study Reveals Poor Prognosis in Patients Converting from ER-Positive to ER-Negative

Omission of surgery in early breast cancer: Are we ready for a paradigm shift?

Advancing precision oncology with metabolomics and machine learning

Risk-based breast cancer screening: A shift toward personalized prevention

Temocillin in the Spotlight: Dr. Francesco Cogliati Dezza on Tackling Antimicrobial Resistance

Professor Li Zhang’s Team Publishes Again in Nature Medicine

Mok Talk | Lung Cancer Leadership, Innovation, and the Power of Collaboration

Temocillin in the Spotlight: Dr. Francesco Cogliati Dezza on Tackling Antimicrobial Resistance

Advancing the Diagnosis and Prevention of Congenital CMV: Insights from Dr. Marianne Leruez-Ville

Temocillin and the Search for Carbapenem Alternatives: A Conversation with Dr. Francesco Cogliati Dezza at ESCMID Global 2025

Prof. Lin Visits MGH | Talk with Prof. Lori Wirth on Targeted Therapy for Advanced Thyroid Cancer

Summit Dialogue | Professors Zhang Guojun & Michael Gnant: New Frontiers in Neoadjuvant Therapy for HER2-Positive Breast Cancer

SABCS China Voice | Professor Wang Biyun: Beware of ER Loss — Study Reveals Poor Prognosis in Patients Converting from ER-Positive to ER-Negative

SABCS China Voice | Prof. Wang Yongsheng: Ki-67–Guided Precision Strategies and Multi-Omics Insights Reshape Breast Cancer Neoadjuvant Therapy

SABCS China Voice | Prof. Wang Yongsheng: Ki-67–Guided Precision Strategies and Multi-Omics Insights Redefine Neoadjuvant Breast Cancer Treatment

Welcome to Mediamedic 👋
It’s nice to meet you.

Welcome to Mediamedic 👋It’s nice to meet you.

Welcome to Mediamedic 👋
It’s nice to meet you.